314 related articles for article (PubMed ID: 31960922)
1. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
2. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of TRAF4 targeting RSK4 inhibits proliferation, invasion and metastasis in breast cancer xenografts.
Zhu L; Zhang S; Huan X; Mei Y; Yang H
Biochem Biophys Res Commun; 2018 Jun; 500(3):810-816. PubMed ID: 29684350
[TBL] [Abstract][Full Text] [Related]
4. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Serra V; Eichhorn PJ; García-García C; Ibrahim YH; Prudkin L; Sánchez G; Rodríguez O; Antón P; Parra JL; Marlow S; Scaltriti M; Pérez-Garcia J; Prat A; Arribas J; Hahn WC; Kim SY; Baselga J
J Clin Invest; 2013 Jun; 123(6):2551-63. PubMed ID: 23635776
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
6. MiR-202-5p/
Liu T; Guo J; Zhang X
Cancer Biol Ther; 2019; 20(7):989-998. PubMed ID: 30983514
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Kang JH; Song KH; Jeong KC; Kim S; Choi C; Lee CH; Oh SH
BMC Cancer; 2011 Aug; 11():334. PubMed ID: 21813027
[TBL] [Abstract][Full Text] [Related]
8. DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT.
Shen M; Cao S; Long X; Xiao L; Yang L; Zhang P; Li L; Chen F; Lei T; Gao H; Ye F; Bu H
Redox Biol; 2024 Apr; 70():103035. PubMed ID: 38306757
[TBL] [Abstract][Full Text] [Related]
9. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
Zhong J; Zhang J; Yu X; Zhang X; Dian L
Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
[TBL] [Abstract][Full Text] [Related]
10. Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.
Li Y; Zhai Z; Li H; Wang X; Huang Y; Su X
Chem Biol Interact; 2019 May; 305():98-104. PubMed ID: 30929998
[TBL] [Abstract][Full Text] [Related]
11. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.
Yu J; Chen WX; Xie WJ; Chen RW; Lin DQ; You WW; Ye WL; Zhang HQ; Lin DH; Xu JP
J Clin Lab Anal; 2021 Aug; 35(8):e23817. PubMed ID: 34114685
[TBL] [Abstract][Full Text] [Related]
12. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
[TBL] [Abstract][Full Text] [Related]
13. Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways.
Wei T; Xiaojun X; Peilong C
Biomed Pharmacother; 2020 Jan; 121():109139. PubMed ID: 31707337
[TBL] [Abstract][Full Text] [Related]
14. RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells.
Zhu J; Li QY; Liu JL; Wei W; Yang HW; Tang W
Oncol Rep; 2015 Dec; 34(6):3156-62. PubMed ID: 26397146
[TBL] [Abstract][Full Text] [Related]
15. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
16. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of RSK4 in breast cancer and its role in the regulation of tumorigenicity.
Jiang Y; Ye X; Ji Y; Zhou X; Yang H; Wei W; Li Q
Int J Mol Med; 2017 Sep; 40(3):883-890. PubMed ID: 28731146
[TBL] [Abstract][Full Text] [Related]
18. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
19. USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/AKT pathway.
Sun J; Xiang Q; Ding D; Yan N
J Bioenerg Biomembr; 2023 Dec; 55(6):457-466. PubMed ID: 37919637
[TBL] [Abstract][Full Text] [Related]
20. Targeting breast cancer stem cells by a self-assembled, aptamer-conjugated DNA nanotrain with preloading doxorubicin.
Xu Z; Ni R; Chen Y
Int J Nanomedicine; 2019; 14():6831-6842. PubMed ID: 31695364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
